
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Growth'hormone'(GH) Somatotroph Liver Insulin8like'growth'
factor'(IGF8I)
Growth/metabolism
Prolactin'(PRL) Lactotroph Mammary'glands n/a Lactation
Adrenocorticotropic'
hormone'(ACTH)



















































First&Author,&Year& N GH LH/FSH ACTH TSH Hypopituitarism Multiple&Deficiencies
Bondanelli,*2004 50 4 7 0 5 14 6
Aimaretti,*2005 70 14 8 4 5 16 7
Agha,*2004 102 18 12 23 1 29 6
Popovic,*2004 67 10 6 5 3 23 7
Agha,*2005 48 5 6 9 1 ND ND
Schnieder,*2006 70 7 14 6 2 25 3
Tanriverdi,*2006 52 17 4 10 3 26 5
Klose,*2007 104 18 2 5 2 18 6
Bushnik,*2007 64 23 7 39 12 58 ND
Bavisetty,*2008 70 11 7 0 0 15 5
Kleindienst,*2009 23 9 0 11 0 ND ND
Srinivasan,*2009 18 4 0 9 4 10 5
Van*der*Eerden,*2010 107 1 7 6 1 15 0
Kokshoorn,*2011 112 3 1 2 ND 6 0
LealKCerro,*2005 170 6 29 11 10 42 15
Hermann,*2006 76 6 13 2 2 18 5
Total*TBI,*n 1203 156 123 142 51 315 70
Total*TBI,*% 100% 13.0% 10.2% 11.8% 4.2% 27.8% 6.2%
Total*TBI*all*GCS,*n 957 144 81 129 39 255 50
Total*TBI*all*GCS,*% 100% 15.0% 8.5% 13.5% 4.1% 28.8% 5.6%
Total*TBI*GCS*≤8,*n 246 12 42 13 12 60 20






























First&Author,&Year&(Ref) N GH LH/FSH ACTH TSH Hypopituitarism Multiple&Deficiencies
Pathological*screening*tests
Agha,*2004 102 18 12 23 1 29 6
Klose,*2007 104 18 2 5 2 18 6
Van*der*Eerden,*2010 107 1 7 6 1 15 0
Total*N 313 37 21 34 4 62 12
Total*% 100% 11.8% 6.7% 10.9% 1.3% 19.8% 3.8%
Pathological*confirmatory*tests*
Agha,*2004 102 11 12 13 1 29 6
Klose,*2007 104 16 2 5 2 16 6
Van*der*Eerden,*2010 107 0 0 1 0 1 0
Total*N 313 27 14 19 3 46 12





































































































































































































































































































































































































































































































































































































































































































































































































































































1× GE-180 PET-CT 
Healthy volunteers 




Chronic neuroinflammation after TBI - Study Design 13/LO/1596 v1.0 (4/10/2013) 
Metabolic assessment;  
Genetic analysis; MRI; 
 Cognitive assessment; 
1× GE-180 PET-CT 
n=40 
Metabolic assessment;  
Genetic analysis; MRI; 
 Cognitive assessment; 

























































































































































































Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L)
or specific treatment for this lipid abnormality 
Reduced HDL cholesterol < 40 mg/dL (1.03 mmol/L) in males 
< 50 mg/dL (1.29 mmol/L) in females 
or specific treatment for this lipid abnormality 
Raised blood pressure systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg
or treatment of previously diagnosed hypertension 
Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L),





















































































































No.	 Duration	(sec)	 Frames	 Time	(cumulative	
secs)	
0	 30	 0	 30	
1-6	 15	 6	 90	
7-9	 60	 3	 180	
10-14	 120	 5	 600	
15-19	 300	 5	 1500	










































































































































































































































































































































































































































































































































































































































































Pituitary Axis 1st Test Confirmatory test
GH Deficiency Glucagon Stimulation Test: peak GH < 5µg/L GHRH-Arginine Test: 
  GH < cut off based on age and BMI{Colao};
  OR ITT: peak GH <3 µg/L
ACTH Deficiency Glucagon Stimulation Test: Metyrapone Test: 11-DOC <200 nmol/L (<6.9 µg/dL)
 peak cortisol <350 nmol/L (<12.7 µg/dL)   OR if unavailable ACTH <60 ng/L 
  despite cortisol < 200nmol/L (<7.2 µg/dL);
OR ITT: peak cortisol <450 nmol/L (<16.3 µg/dL)
Supported by AM cortisol <100 nmol/L (<3.62 µg/dL)
Hyperprolactinemia Prolactin >375 mU/L (NR 75-375) Repeat prolactin >375 mU/L 
  AND negative Macroprolactin 
  AND normal MRI pituitary with contrast
Gonadotrophin Deficiency Random testosterone <10 nmol/L (<2.9 ng/mL) Repeat abnormal basal levels 
  OR if SHBG low (<15 nmol/L) FAI <30,   using morning (9-10am) sample
  AND non-elevated LH (NR 1.7-12.0 IU/L)
  and FSH (NR 1.7-8.0 IU/L) 
TSH Deficiency Free T4 <9.0 pmol/L (<0.70 ng/dL) Repeat abnormal basal levels 
  OR free T3 <2.5 pmol/L (<0.16 ng/dL),
  AND non-elevated TSH (NR 0.30-4.22 mU/L)
























































































































































  units 
/ max 
score 







n   39 19   13 6   
Age at TBI         yr. 31.3 [22.5-
35.7] 
26.7 [26.1-30.9] 0.40 26.6 [24.6-30.6] 29.3 [25.8-
36.6] 
0.48 
    17.2 - 44.8 19.0 - 43.5   19.0 - 36.3 25.0 - 43.5   
Age at testing  yr. 32.3 [23.1-
36.7] 
28.3 [26.8-32.2] 0.40 28.0 [25.3-31.4] 30.3 [27.4-
38.3] 
0.32 
    19.9 - 45.1 19.6 - 44.7   19.6 - 37.6 26.3 - 44.7   
Time since TBI mo 5.8 [3.1-
11.0] 
15.2 [10.8-19.3] 0.001 15.2 [8.8-16.6] 17.6 [12.3-
20.2] 
0.32 
    1.9-41.2 4.1 - 23.7   4.1-23.7 4.9-21.9   
ISS  75 25.0 [16.0-
32.0] 
33.0 [20.0-45.0] 0.17 24.0 [14.5-40.5] 35.5 [27.0-
51.3] 
0.24 
    1-75 9-70   9-45 9-70   
AIS Head  6 5.0 [4.0-5.0] 4.0 [3.0-5.0] 0.04 4.0 [2.5-4.0] 5.0 [3.0-5.3] 0.06 
    1-6 0-6   0-5 0-6   
AIS Chest  6 0 [0-0] 0 [0-2] 0.11 0 [0-3] 0.5 [0-2.3] 0.83 
    0-6 0-4   0-4 0-3   
AIS Abdomen  6 0 [0-0] 0 [0-2] 0.02 0 [0-2] 0 [0-2.3] 0.97 
    0-3 0-3   0-2 0-3   
GCS 15 14.0 [6.0-
14.0] a 
3.0 [3.0-14.5] b 0.24 14.0 [3.0-15.0] c 3.0 [3.0-3.0] d 0.19 
    3-15 3-15   3-15 3-3   
PTA  days 0.5 [0-7.3] e 5.5 [0.8-22.8] 0.01 3.0 [0-19.3] 15.5 [6.3-31.5] 0.10 
    0-42  0-84   0-84 4-42   
PTA>24 hrs   20 (51.3%) 13 (68.4%) 0.27 7 (58.3%) 6 (100%) 0.11 
BMI  kg/m2 24.7 [22.4-
29.4] 
26.7 [24.5-28.9] 0.28 26.6 [24.5-28.7] f 25.5 [22.4-
32.0] g 
0.79 
    17.0-33.4 21.7-33.7   23.6-29.4 21.7-33.7   
Limb amputation   0 (0%) 8 (42.1%) <0.001 6 (46.1%) 2 (33.3%)  1.00 
Major organ 
damage 
  3 (7.7%) 11 (57.9%) <0.001 7 (53.9%) 4 (66.7%) 1.00 
Skull/facial 
fracture 
  6 (15.4%) 3 (15.8%) 1.0 0 (0%) 3 (50.0%)  0.02 
Opiate use   3 (7.7%) 9 (47.3%)  0.001 6 (46.2%) 3 (50.0%) 1.00 
Anti-depressant 
use 
  5 (12.8%) h 10 (52.7%) i 0.003 7 (53.8%) j 3 (50.0%) k 1.00 
Seizures post 
TBI 
  3 (7.7%) l 2 (10.5%) m 1.0 1 (7.7%) n 1 (16.7%) o 1.00 
Primary 
hypogonadism 
































Prevalence of Pituitary Dysfunction:
nbTBI 2.6% bTBI 31.6%








































GROWTH HORMONE / IGF-1 AXIS
Glucagon Stimulation Test GHRH-Arginine Test    Insulin Tolerance Test
ID Summary of Pituitary Dysfunction IGF-I 
IGF-I                      
age related NR
IGF-I             
median of NR
IGF-I                 
ratio to median Peak GH IGF-I BMI GH cut off Peak GH IGF-I Peak GH
Units nmol/L nmol/L nmol/L n/a µg/L nmol/L kg/m2 µg/L µg/L nmol/L µg/L
Normal range >5 >5
No Pituitary Dysfunction n=13
M02 Nil 22.6 14.2-36.9 22.9 0.72 6.55 n/a n/a n/a n/a 23.5 52.10
M04 Nil 58.0 15.2-42.8 25.5 1.84 13.10 n/a n/a n/a n/a n/a n/a
M05 Nil 19.9 15.2-42.9 25.5 0.63 11.60 n/a n/a n/a n/a n/a n/a
M09 Nil 29.0 18.3-62.8 33.9 0.62 0.98 18.7 n/a 11.7 17.20 n/a n/a
M11 Nil 31.9 16.5-55.1 30.2 1.01 1.56 31.9 26.6 11.7 37.80 n/a n/a
M12 Nil 38.1 15.2-42.8 25.5 1.21 0.64 38.1 n/a 8.1 13.50 n/a n/a
M13 Nil 74.5 15.1-46.5 26.4 2.37 0.69 ND n/a 11.7 17.30 n/a n/a
M15 Nil 27.4 15.2-42.8 25.5 0.87 2.84 30.0 n/a 8.1 23.30 n/a n/a
M16 Nil 31.3 14.2-36.9 22.9 0.99 3.17 29.8 28.7 8.1 27.00 n/a n/a
M17 Nil 19.9 15.2-42.8 25.5 0.63 8.66 n/a n/a n/a n/a n/a n/a
M18 Nil 17.9 15.2-42.8 25.5 0.57 2.65 19.9 n/a 8.1 10.00 n/a n/a
M19 Nil 29.6 15.2-42.8 25.5 0.94 5.96 n/a n/a n/a n/a n/a n/a
M20 Nil 17.2 15.0-39.9 24.4 0.55 7.96 n/a n/a n/a n/a n/a n/a
Median [IQR] 29.0 [19.9-35.0] 0.87 [0.63-1.11] 3.17 [1.27-8.31] 29.9 [19.6-33.5] 17.30 [13.50-27.00]
Range 17.2-74.5 0.55-2.37 0.64-13.10 19.0-38.0 10.0-38.0
Pituitary dysfunction n=6
M01 PRL 21.6 15.2-42.8 25.5 0.69 6.97 n/a n/a n/a n/a n/a n/a
M03 ACTH 26.7 15.2-42.8 25.5 0.85 0.19 32.1 31.6 8.1 15.40 n/a n/a
M07 GH 23.7 15.0-39.9 24.4 0.75 2.66 26.1 26.1 5.5 3.43 n/a n/a
M08 ACTH/GH/Gn 16.1 13.1-34.7 21.3 0.66 0.08 16.6 n/a 8.1 4.26 ND 0.18
M10 PRL 18.9 15.2-42.8 25.5 0.60 2.78 29.4 24.3 8.1 25.80 n/a n/a
M14 GH 18.2 15.2-42.8 25.5 0.58 0.05 21.8 33.7 5.5 2.70 n/a n/a
Median [IQR] 20.3 [17.7-24.5] 0.68 [0.60-0.78] 1.43 [0.07-3.83] 26.1 [19.2-30.8] 4.26 [3.07-20.6]
Range 16.1-26.7 0.58-0.85 0.05-6.97 16.6-32.1 2.70-25.80







Glucagon Stress Test Day Curve Metyrapone Test (post levels) Insulin Tolerance Test
ID Summary of Pituitary Dysfunction Basal Cortisol 
a Peak Cortisol a Basal ACTH Cortisol a Cortisol a ACTH 11-DOC b Basal Cortisol a Peak Cortisol a CBG  
Units nmol/L nmol/L ng/L nmol/L nmol/L ng/L nmol/L nmol/L nmol/L µg/L
Normal Range 100-500 >350 <50 09, 12, 15, 18, 21h <200 >60 >200 100-500 >500 27.1-52.3
No Pituitary Dysfunction n=13
M02 Nil 230 230 6.0 304, 208, 226, 295, ND n/a n/a n/a 544 636 48.9
M04 Nil 283 378 27.4 395, 153, 136, 72, 54 123 247 244.5 n/a n/a n/a
M05 Nil 309 494 39.2 n/a n/a n/a n/a n/a n/a n/a
M09 Nil 335 389 15.3 n/a n/a n/a n/a n/a n/a n/a
M11 Nil 323 473 38.0 n/a n/a n/a n/a n/a n/a n/a
M12 Nil 192 478 17.2 n/a n/a n/a n/a n/a n/a n/a
M13 Nil 363 386 24.6 n/a n/a n/a n/a n/a n/a n/a
M15 Nil 376 497 ND n/a n/a n/a n/a n/a n/a n/a
M16 Nil 427 427 92.7 n/a n/a n/a n/a n/a n/a n/a
M17 Nil 207 626 20.0 n/a n/a n/a n/a n/a n/a n/a
M18 Nil 409 533 27.0 n/a n/a n/a n/a n/a n/a n/a
M19 Nil 220 435 19.7 n/a n/a n/a n/a n/a n/a n/a
M20 Nil 420 420 28.6 n/a n/a n/a n/a n/a n/a n/a
Median [IQR] 323.0 [225.0-392.5] 435.0 [387.5-495.5] 25.8 [17.8-35.7]
Range 192-427 230-626 6.0-92.7
Pituitary dysfunction n=6
M01 PRL 606 606 164.0 n/a n/a n/a n/a n/a n/a n/a
M03 ACTH 292 292 23.2 67, 50, <20, 28, <20 38 22 87.1 n/a n/a 63.0
M07 GH 419 419 24.8 n/a n/a n/a n/a n/a n/a n/a
M08 ACTH/GH/Gn 287 287 18.7 204, 86, 100, 44, 22 n/a n/a n/a 110 268 74.0
M10 PRL 109 350 20.6 422, 333, 200, 260, 79 ND 207 200.0 n/a n/a 55.7
M14 GH 88 445 32.2 200 at 13h n/a n/a n/a n/a n/a n/a
Median [IQR] 289.5 [103.8-465.8] 384.5 [290.8-485.3] 24.0 [20.1-65.2]
Range 88-606 287-606 18.7-164.0






GONADOTROPHIN / TESTOSTERONE AXIS THYROID PROLACTIN
ID Summary of 
Pituitary Dysfunction
LH                         FSH                     Testosterone SHBG                 Free Androgen Index 
Primary 
Hypogonadism Free T4            Free T3         TSH Prolactin                               
Units IU/L IU/L nmol/L nmol/L pmol/L pmol/L mU/L mU/L
Normal range 2.0-12.0 1.7-8.0 10.0-30.0 15-55 30-150 9.0-26.0 2.5-5.7 0.3-4.2 75-375
No Pituitary Dysfunction n=13
M02 Nil 2.4 1.1 23.7 55.0 43.1 No 15.6 4.4 0.46 97
M04 Nil 4.7 3.9 21.0 33.0 63.6 No 12.2 5.7 2.11 146
M05 Nil 4.4 2.5 15.5 18.0 86.1 No 15.3 3.2 1.78 118
M09 Nil 1.2 4.8 39.5 18.0 219.4 Yes 13.4 5.8 1.04 219
M11 Nil 1.6 0.7 12.5 18.0 69.4 No 14.0 4.4 1.43 285
M12 Nil 18.5 36.4 6.2 10.0 62.0 Yes 15.5 3.5 1.21 177
M13 Nil 5.8 9.6 13.1 10.0 131.0 No 13.2 5.2 1.33 240
M15 Nil 40.3 60.3 11.6 18.0 64.4 Yes 14.0 6.6 0.77 136
M16 Nil 5.5 4.9 22.3 24.0 92.9 No 13.4 4.4 0.96 200
M17 Nil 4.7 3.3 25.2 39.0 64.6 No 16.9 5.2 1.13 131
M18 Nil 0.0 0.1 12.3 19.0 64.7 Yes 18.5 4.8 1.25 312
M19 Nil 2.3 1.5 22.0 28.0 78.6 No 15.0 4.7 2.06 183
M20 Nil 3.8 3.6 28.8 32.0 90.0 No 13.2 4.6 0.70 330
Median [IQR] or n (%) 4.4 [2.0-5.6] 3.6 [1.3-7.3] 21.0 [12.4-24.5] 19.0 [18.0-32.5] 69.4 [64.0-91.5] 4 (30.8%) 14.0 [13.3-15.6] 4.7 [4.4-5.5] 1.21 [0.87-1.61] 183 [134-263]
Range 0-40.3 0.1-60.3 6.2-39.5 10.0-55.0 43.1-219.4 12.2-18.5 3.2-6.6 0.46-2.11 97-330
Pituitary dysfunction n=6
M01 PRL 1.8 2.5 21.7 27.0 80.4 No 17.3 4.6 4.18 619
M03 ACTH 1.5 1.2 23.8 35.0 68.0 No 16.0 5.5 1.11 126
M07 GH 3.7 2.4 13.1 24.0 54.6 No 14.4 4.9 1.81 172
M08 ACTH/GH/Gn 1.3 1.8 2.0 18.0 11.1 No 15.5 4.3 1.19 199
M10 PRL 2.6 1.3 22.8 26.0 87.7 No 10.8 4.7 2.29 439
M14 GH 6.5 3.9 22.4 33.0 67.9 No 12.9 4.0 0.90 216
Median [IQR] or n (%) 2.2 [1.5-4.4] 2.1 [1.3-2.9] 22.1 [10.3-23.1] 26.5 [22.5-33.5] 68.0 [43.7-82.2] 0 (0%) 15.0 [12.4-16.3] 4.7 [4.2-5.1] 1.50 [1.06-2.76] 208 [161-484]
Range 1.3-6.5 1.2-3.9 2.0-23.8 18.0-35.5 11.1-87.7 10.8-17.3 4.0-5.5 0.90-4.18 126-619















Units / Maximum score Years Years Months 75 6 6 6 15 Days kg/m
2
No pituitary dysfunction (n=13)
M02 36.3 37.6 15.2 20 4 0 2 3 1 25.4 No No No No Yes Yes No
M04 26.4 27.6 14.2 24 0 4 0 n/a 4 27.7 Yes No Lung/eye No No No No
M05 27.3 28.6 15.2 24 0 4 0 n/a 28 24.5 Yes No No No Yes No No
M09 19.0 19.6 6.7 45 4 0 2 n/a 4 n/a Yes Yes Perineum No Yes Yes * No
M11 19.3 20.9 16.6 25 5 0 0 3 84 26.6 Yes No No No No No Yes
M12 30.2 30.5 4.1 33 2 0 2 n/a 0 n/a No Yes Perineum No Yes Yes * No
M13 22.8 23.7 10.8 45 4 0 0 n/a 21 n/a Yes Yes Eye/Skin No No Yes * No
M15 26.4 26.8 4.1 45 4 0 2 15 0 n/a No Yes Eye/Skin/perineum No Yes Yes * No
M16 34.7 36.7 23.7 24 4 2 0 15 0 28.7 No No No No Yes Yes No
M17 26.6 28.0 16.6 9 3 0 0 14 0 23.6 No No No No No No No
M18 26.7 28.3 20.2 36 4 4 2 n/a 14 n/a Yes Yes Lung/colon/perineum No No No No
M19 26.6 27.7 13.6 9 3 0 0 n/a n/a n/a n/a Yes Skin No No No No
M20 30.9 32.2 15.4 9 3 0 0 n/a 2 29.4 Yes No No No No Yes No
median 26.6 28.0 15.2 24.0 4.0 0 0 3.0 26.6 7 (58.3%) 6 (46.1%) 7 (53.9%) 0 (0%) 6 (46.2%) 7 (53.8%) 1 (7.7%)
IQR [24.6-30.6]  [25.3-31.4] [8.8-16.6]  [14.5-40.5] [2.5-4.0]  [0-3] [0-2] [0-19.3]  [24.5-28.7]
Pituitary dysfunction (n=6)
M01 (PRL) 30.0 30.4 4.9 33 5 0 0 3 4 21.7 Yes No No Yes Yes Yes * Yes #
M03 (ACTH) 25.0 26.3 15.9 70 6 0 3 3 17 n/a Yes Yes Spleen/Liver Yes No Yes * No
M07 (GH) 34.3 36.2 21.9 38 5 3 0 3 7 26.7 Yes No Lung No No No No
M08 (ACTH/GH/Gn) 43.5 44.7 14.7 45 4 2 0 n/a 42 n/a Yes Yes No No Yes No No
M10 (PRL) 28.5 30.1 19.3 33 5 0 2 n/a 28 24.3 Yes No Eye/Liver/lung Yes No No No
M14 (GH) 26.1 27.7 19.6 9 0 1 0 3 14 33.7 Yes No Skin No Yes Yes No
median 29.3 30.3 17.6 35.5 5 0.5 0 15.5 25.5 6 (100%) 2 (33.3%) 4 (66.7%) 3 (50.0%) 3 (50%) 3 (50%) 1 (16.7%)
IQR [25.8-36.6] [27.4-38.3] [12.3-20.2] [27.0-51.3] [3.0-5.3]  [0-2.3]  [0-2.3]  [6.3-31.5] [22.4-32.0]
















No pituitary dysfunction (n=13)
M02 Diclofenac, Sertraline, Tramadol
M04 Co-codamol
M05 Diclofenac, Tramadol
M09 Amitriptyline, MST, Nebido, Pregabalin
M11 None
M12 Amitriptyline, Diclofenac, Nebido, Pregabalin, Ranitidine, Sildenafil, Tramadol
M13 Amitriptyline, Baclofen, Pregabalin
M15 Amitriptyline, Nebido, Pregabalin, Tramadol
M16 Mirtazepine, Paracetamol, Pregabalin, Tramadol, Zopiclone 
M17 None
M18 Nebido
M19 Diclofenac, Pregabalin, Ranitidine
M20 Sertraline, Zopiclone
Pituitary dysfunction (n=6)
M01 (PRL) Amitriptyline, Diclofenac, MST, Phenytoin
M03 (ACTH) Amitriptyline, Erythromycin, Gabapentin
M07 (GH) None
M08 (ACTH/GH/Gn) Diclofenac, Lansoprazole, MST, Paracetamol, Pregabalin, Tramadol
M10 (PRL) Betnovate ointment, Co-codamol

























No pituitary dysfunction Pituitary dysfunction P
 n 13 6
 Acute CT brain
Extra-dural hemorrhage 0 (0%) 0 (0%) n/a
Sub-dural hemorrhage 0 (0%) 0 (0%) n/a
Traumatic sub-arachnoid or 
intra-ventricular hemorrhage 0 (0%) 0 (0%) n/a
Diffuse swelling 1 (7.7%) 0 (0%) 1.00
 Study MRI brain
Contusion 1 (7.7%) 3 (50.0%) 0.07
Siderosis 3 (23%) 1 (16.6%) 1.00
Microbleeds 7 (53%) 3 (50%) 1.00
Gliosis 0 (0%) 1 (16.6%) 0.32
Hypo-pituitary damage 0 (0%) 0 (0%) n/a
 MRI pituitary with contrast ND 4 normal, 2 ND n/a
Data given as n (%)
















































 Quality of Life / Symptom Assessment nbTBI All bTBI P value                 nbTBI vs. bTBI




P  value                         
no pit dys vs. pit dys
n 38 18 h 12 h 6
Assessment of GH Deficiency in Adults (AGHDA)  9.5 [5.8-14.5] a  16.0 [4.0-18.5] b 0.22  14.0 [3.0-17.0]  17.5 [16.0-19.5] 0.10
Beck Depression Inventory Score (BDI-II)  11.0 [7.0-20.0] c  20.5 [4.0-24.5] 0.30  11.5 [1.8-21.8]  24.5 [20.3-26.3] 0.08
Epworth Sleepiness Scale  7.0 [2.0-12.0] d  7.0 [2.5-11.0] 0.89  6.0 [1.5-10.5]  10.0 [3.0-16.5] 0.25
Pittsburgh Sleep Index  ND  10.0 [2.8-16.0]  4.5 [2.0-16.3]  12.0 [8.0-15.5] 0.37
NHP Energy Levels         39.0 [0-100] e  49.0 [18.0-100] 0.63  49.0 [0-94.0]  68.5 [24.0-100] 0.39
NHP Pain                    0 [0-48] e  28.5 [9.7-52.5] 0.08  24.0 [14.0-51.0]  36.0 [0-54.5] 0.96
NHP Emotional Reactions  20.0 [10.0-47.0] e  32.5 [6.7-55.5] 0.71  15.0 [0-46.2]  54.0 [25.0-67.7] 0.10
NHP Sleep        22.0 [0-73.0] e  55.0 [0-100] 0.20  30.0 [0-93.2]  64.0 [31.7-100] 0.29
NHP Social Isolation   0 [0-45.0] e  21.0 [0-59.0] 0.52  0 [0-48.5]  29.0 [21.2-69.0] 0.13
NHP Physical Activity         0 [0-21.8] e  26.5 [11.0-42.0] 0.02  26.5 [13.2-42.0]  27.0 [0-60.7] 0.96
NHP Average              22.0 [5.4-41.0] e  41.5 [15.5-55.2] 0.09  28.5 [9.5-55.0]  48.5 [38.7-55.2] 0.25
NHP Daily Living Problems (0-7)  2.0 [0-5.0] f  5.0 [3.5-6.0] 0.04  4.5 [2.3-5.8]  4.5 [3.8-6.3] 0.62
SF-36 Physical functioning  85.0 [60.0-95.0] e  52.5 [27.5-81.3] 0.21  52.5 [41.3-58.8]  60.0 [27.5-88.8] 0.82
SF-36 Role limitations due to physical health  12.5 [0-62.5] g  12.5 [0-75.0] 0.94  25.0 [0-93.8]  0 [0-18.8] 0.10
SF-36 Role limitations due to emotional problems  67.0 [0-100] g  67.0 [24.8-100] 0.90  83.5 [33.0-100]  50.0 [0-100] 0.49
SF-36 Energy/Fatigue  50.0 [35-60] e  42.5 [33.8-66.3] 0.92  52.5 [36.3-70.0]  37.5 [26.3-47.0] 0.15
SF-36 Emotional well being  64.0 [52.0-80.0] e  60.0 [48.0-81.0] 0.57  68.0 [53.0-83.0]  58.0 [31.0-66.3] 0.34
SF-36 Social functioning  63.0 [38.0-75.0] e  50.0 [38.0-75.0] 0.66  56.5 [41.0-84.8]  44.0 [22.0-63.0] 0.18
SF-36 Pain  55.0 [33.0-88.0] e  45.0 [33.0-70.5] 0.68  68.0 [35.5-75.5]  33.0 [23.0-58.8] 0.21
SF-36 Health change  50.0 [38.0-75.0] e  32.5 [25.0-50.0] 0.06  25.0 [25.0-50.0]  45.0 [25.0-56.3] 0.49











Cognitive domain Cognitive variable No pituitary dysfunction Pituitary dysfunction
n=13 n=6
Pre-morbid intelligence: reading ability WTAR raw score 35.9 ± 11.7 34.7 ± 14.6
Intellectual ability WASI similarities (verbal) 32.6 ± 6.2 27.0 ± 4.1 *
WASI matrix reasoning (non-verbal) 24.4 ± 7.5 24.2 ± 6.0
Memory: associative memory People test immediate recall 22.6 ± 8.1 25.0 ± 7.8
Processing speed: visual search/complex Trail Making Test Trail A (s) 23.1 ± 5.7 28.7 ± 5.2 *
Trail Making Test Trail B (s) 47.9 ± 14.5 53.8 ± 12.2
Processing speed: naming/reading Stroop Colour Naming (s) 32.5 ± 9.1 51.0 ± 29.7 *
Stroop Word Reading (s) 24.3 ± 6.7 37.2 ± 13.6 **
Executive function: alternating-switch cost Trail Making Test Trail B minus A (s) 24.8 ± 13.5 25.2 ± 9.0
Executive function: cognitive flexibility Color Word Stroop Inhibition/switching (s) 70.5 ± 24.2 86.3 ± 30.8
Inhibition/switching minus a baseline of 30.0 ± 18.8 26.5 ± 8.5
        color naming and word reading (s)
Word generation fluency DKEFS Letter Fluency F+A+S total 40.1 ± 12.9 28.8 ± 3.6 *
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All Group Above Median IGF-I Below Median IGF-I
P Above vs 
Belowa
n 39 22 17
Age at first scan (yrs) 30.5 [24.5-47.0] 30.2 [24.3-47.6] 34.5 [25.2-48.8] 0.43
Range 19.6-66.9 19.6-62.2 21.3-66.9
Male Sex                               33 (84.6%) 17 (77.3%) 16 (94.1%) 0.21
Moderate-Severe Severity 34 (87.2%) 20 (90.6%) 14 (82.4%) 0.67
Time since Injury (months) 16.3 [3.6-24.5] 12.5 [4.-25.9] 17.2 [3.1-33.5] 0.89
                                   Range 1.47-571.0 1.5-571.0 1.5-102.9
Time between scans (months) 13.3 [12.1-14.9] 12.35 [10.81-13.4] 14.4 [13.1-15.1] 0.08
Range 6.3-24.6 6.3-24.6 8.87-17.8
Absolute IGF-1 nmol/Lb 23.8 [19.2-29.5] 28.2 [23.3.-35.1] 19.9 [16.8-23.7] 0.02
Range 12.8-74.5 19.2-74.5 12.8-29.0
Age-Adjusted IGF-1 Ratio 1.1 [0.9-1.2] 1.2 [1.1-1.5] 0.8 [0.8-0.9] <0.001
Range 0.6-3.0 1.0-2.9 0.6-1.0
GHD 4 (10.2%) 1 (4.5%) 3 (17.6%) 0.30
Any Pituitary Deficiency 7 (17.9%) 3  (13.6%) 4 (23.5%) 0.68
Blast Injury 13 (33.3% 8 (36.3%) 5 (29.4%) 0.74
Any structural brain abnormality 30 (76.9%) 19 (86.4%) 11 (64.7%) 0.14
≥ 1 contusion 20 (51.3%) 11 (28.2%) 9 (52.9%) 1.00
Average  no. of contusions* 1.7 2.8 2
≥ 1 microbleed 10 (25.6%) 8 (36.4%) 2 (11.8%) 0.14
Superficial siderosis 13 (33.3%) 6 (27.3%) 7 (41.2%) 0.50
Diffuse axonal injury (DAI) 5 (12.8%) 3 (13.6%) 2 (11.8%) 1.00
BMI 25.3 [23.1-29.8] 23.6 [19.6-29.0] 25.3 [24.4-30.2] 1.00
17.0-35.0 17.0-32.3 21.3-35.0
















All No GHD With GHD
P with vs 
without GHDa
n 39 35 4
Age at first scan (yrs) 30.5 [24.5, 47.0] 30.4 [24.1, 49.2] 39.4 [29.7, 44.4] 0.50
Range 19.6-66.9 19.6-66.9 27.8-44.7
Male Sex                               33 (84.6%) 29 (82.9%) 4 (100%) 1.00
Moderate-Severe Severity 34 (87.2%) 30 (85.7%) 4 (100%) 1.00
Time since Injury (months) 16.3 [3.6, 24.5] 11.4 [3.2, 25.7] 26.8 [7.7-34.3] 0.38
                                   Range 1.5-571.0 1.5-571.0 3.6-34.5
Time between scans (months) 13.3 [12.1, 14.9] 13.1 [12.1, 14.5] 14.6 [10.3-15.1] 0.58
Range 6.3-24.6 6.3-24.6 9.1-15.1
Absolute IGF-1 nmol/Lb 23.8 [19.2-29.5] 24.2 [19.5, 29.5] 19.6 [16.7, 23.2] 0.11
Range 12.8-74.5 12.8-74.5 16.5-23.7
Age-Adjusted IGF-1 Ratio 1.1 [0.9, 1.2] 1.1 [0.9, 1.3] 0.9 [0.8-1.0] 0.11
Range 0.6-3.0 0.6-2.9 0.8-1.0
Blast Injury 13 (33.3% 10 (28.6%) 3 (75.0%) 0.10
Any structural brain abnormality 30 (76.9%) 28 (80.0%) 2 (50.0%) 0.22
≥ 1 contusion 20 (51.3%) 19 (54.3%) 1 (25.0%) 0.34
Average  no. of contusions* 1.7 2.5 n/a
≥ 1 microbleed 10 (25.6%) 10 (28.6%) 0 (0.0%) 0.56
Superficial siderosis 13 (33.3%) 11 (31.4%) 2 (50.0%) 0.59
Diffuse axonal injury (DAI) 5 (12.8%) 4(11.4%) 1 (25.0%) 0.44
BMI 25.3 [23.1-29.8] 25.0 [21.7-28.6] 29.3 [21.7-28.2] 0.10
Range 17.0-35.0 17.0 -25.0 25.3-33.7






















As	 expected,	 compared	 to	 the	 healthy	 control	 group,	 the	 TBI	 group	 overall	 had	
significantly	 lower	 FA	 in	 the	 a	 priori	 ROIs	 SPCC	 (effect	 size	mean	 ±	 SEM	 -0.021	 ±	













































































































































Time: F(1,32) = 0.15, P=0.70
Group: F(1,32) = 0.12, P=0.74
Time x Group interaction: F(1,32) 
=5.72, P=0.023
Effect of:
Time: F(1,32) = 0.34, P=0.56
Group: F(1,32) = 1.01, P=0.32



















































































Symptom Domain  n
Max 







Assessment of GH Deficiency in Adults (AGHDA-QoL)a 25 25 9 [2.5-16.5] 0-23 25 7.0 [1-12.5] 0-22 0.99 0.71 0.89
Beck Depression Inventory Score (BDI-II) 25 63 13.0 [4.0-23.0] 0-27 25 11.0 [2.5-18.5] 0-32 0.46 0.75 0.63
Epworth Sleepiness Scale 22 24 3.0 [0.9.5] 0-19 15 4.0 [1.0-10.0] 0-14 0.69 0.45 0.53
SF-36 QoL Physical functioning 16 100 70.0 [22.5-98.8] 0-100 24 87.5 [62.3-95.0] 0-100 0.32 0.82 0.53
Role limitations due to physical health 17 100 75.0 [0-100] 0-100 24 50.0 [6.25-100] 0-100 0.58 0.37 0.58
Role limitations due to emotional problems 16 100 100 [66.7-100] 0-100 24 100 [41.7-100] 0-100 0.88 0.59 0.77
Energy/Fatigue 16 100 45.0 [45.0-70.0] 15-85 24 67.5 [47.5-83.8] 5-100 0.41 0.41 0.12
Emotional well being 16 100 70.0 [54-83.0] 28.0-92.0 24 80.0 [61.0-92.0] 24.0-100 0.52 0.75 0.96
Social functioning 17 100 62.5 [50.0-75.0] 12.5-100.0 24 81.3 [50.0-100] 25-100 0.22 0.77 0.87
Pain 17 100 45.0 [39.0-83.8] 22.5-100 24 77.5 [55.6-100] 42.5-100 0.74 0.82 0.93
General health 17 100 60.0 [42.5-80.0] 20-100 24 65.0 [45.0-91.3] 15-100 0.27 0.59 0.18
Cognitive domain Cognitive variable
Pre-morbid intelligence: reading ability WTAR raw score 32 41.0 [35.3-45.0] 0-50 32 42.0 [31.8-46.8] 9-50 0.88 0.83 0.60
Intellectual ability WASI similarities (verbal) 33 36.0 [32.5-38.0] 21-46 33 39.0 [35.5-41.0] 23-46 0.61 0.96 0.42
WASI matrix reasoning (non-verbal) 32 26.5 [20.5-30.0] 9-34 32 28.5 [25.3-30.8] 12-35 0.08 1.00 0.20
Memory: associative memory People test (total score) 33 22.0 [14.5-29.0] 4-38 33 27.0 [18.0-31.0] 6-38 0.010 0.19 0.78
Immediate recall Logical memory I Total 33 28.0 [20.5-32.0] 10-40 33 43.0 [33.0-51.5] 19-62 0.26 0.12 0.046
Logical memory II Total 33 26.0 [18.5-32.5] 0-42 33 27.0 [19.5-33.0] 10-43 0.63 0.20 0.57
Delayed Recall Logical memory retention 32 86.7 [78.9-94.3] 33.3-107.7 33 90.3 [82.9-98.0] 45-190 0.41 0.34 0.93
Processing speed: visual search/complex Trail Making Test Trail A (s) 32 26.0 [21.0-32.0] 14-67 33 22.0 [16.5-28.5] 13-87 0.82 0.60 0.65
Trail Making Test Trail B (s) 32 52.0 [43.3-68.5] 22-192 33 47.0 [30.5-71.0] 25-166 0.62 0.32 0.81
Processing speed: naming/reading Stroop Colour Naming (s) 31 32.0 [28.0-41.0] 20-101 33 32.0 [30.0-35.0] 19-51 0.56 0.90 0.96
Stroop Word Reading (s) 31 23.0 [19.0-32.0] 15-62 32 23.0 [20.0-25.8] 14-43 0.53 0.25 0.34
Executive function: alternating-switch cost Trail Making Test Trail B minus A (s) 32 22.5 [13.0-38.8] 4-125 33 19.0 [15.0-42.5] 7-102 0.57 0.24 0.62
Cognitive flexibility Color Word Stroop Inhibition/switching (s) 32 66.0 [55.5-76.5] 38-128 33 57.0 [51.5-66.5] 37-119 0.003 0.33 0.50













either	 the	 SPCC	 or	 PLIC	 ROIs	 (GHD	 status	 x	 time	 interaction	 P=0.29-0.45).	 This	




























































Time: F(1,32) = 0.24, P=0.63
Group: F(1,32) = 2.23, P=0.15
Time x Group interaction: F(1,32) 
=1.55, P=0.22
Effect of:
Time: F(1,32) = 0.44, P=0.51
Group: F(1,32) = 0.09, P=0.77

































































































































































































































































































































































































































INJURY SEVERITY	(MAYO) GENDER MEDICATIONS	AT	INITIATION	OF	GHR
OTHER	PITUITARY	
DEFICIENCES/DIABETES/EPILEPSY STRUCTURAL	MRI	LESIONS PITUITARY	MRI
1 cyclist moderate-severe male levetiracetam,	escitalopram,	venlafaxine,	rampril,	vitamin	D epilepsy siderosis	left	parietal	lobe small	vol	of	pituitary	tissue
2 RTA-pedestrian moderate-severe male carbamazepine,	fluoextine,	quetiapine,	omeprazole epilepsy nil	 hypoplastic	stalk	
3 RTA-pedestrian moderate-severe male phenytoin,	temazepam,	sertralline,	quietapine,	lansoprazole,	codydramol,	ramipril epilepsy cystic	encephalomalacia normal
4 assault moderate-severe male vitamin	D nil left	frontal	haemorrhagic	contusion normal
5 RTA-motorbike moderate-severe male citalopram,	modafinil,	omeprazole nil contusion normal
6 Fall moderate-severe male carbamezpine,	fluoextine,	lorazepam,	zopiclone epilepsy gliosis,	microbleed not	performed
7 RTA-car mild female metformin,	lisinopril,	rosuvastatin,	gliclazide,	bendroflumethiazide,	atenolol,	aspirin type	2	diabetes nil normal
8 RTA-cyclist moderate-severe male vitamin	D nil microhaemorrhages,	contusion,	siderosis normal
9 blast moderate-severe male nebido,	pregabalin,	amitriptyline,	sodium	docusate,	hydrocortisone ACTH	and	gonadotrophin nil normal








n No GHR With GHR
P with vs. 
without 
GHR a
n 33 23 10
Age at first scan (yrs) 33 30.5 [26.8-47.0] 41.7 [26.8-45.4] 0.62
Range 23.1-55.0 22.7 -56.7
Male Sex                               33 20 (87.0%) 9 (90%) 0.74
Moderate-Severe Severity 33 22 (95.7%) 9 (90%) 0.87
Time since Injury (months) 33 19.2 [4.4-23.0] 23.5 [20.5-67.9] 0.21
                                   Range 1.5-25.5 17.6-292.8
Time between scans (months) 33 11.8 [9.0-14.8] 17.1 [13.9-18.9] 0.04
Range 6.3-16.4 11.5-19.4
Absolute IGF-1 nmol/Lb 33 23.0 [15.7-26.7] 20.9 [19.4-23.1] 0.08
Range 12.8-27.0 15.9-31.7
Age-Adjusted IGF-1 Ratio 33 0.9 [0.8-1.0] 1.1 [0.9-1.2] 0.21
Range 0.7-1.1 0.7-1.3
Blast Injury 33 9 (39.1%) 2 (20%) 0.50
Any structural brain abnormality 33 10 (43.4%) 6 (60%) 0.62
BMI (kg/m2) 27 24.9 [21.6-29.5] 28.8 [27.5-33.1] 0.12
Range 20.9-31.6 26.1-33.7
Fasting blood glucose 32 5.2 [4.7-5.2] 5.2 [4.9-7.0] 0.70
Range 4.5-5.4 4.0 -17.0
HbA1c 32 32.5 [30.3-35.2] 38.0 [32.0-43.5] 0.25
Range 4.4-39.0 29.0-53.0
Fasting C-peptide 31 665.0 [381.5-818.3] 861.0 [526.-1167.0] 0.20
Range 247.0-923.0 217.0-2552.0
Fasting insulin 29 6.0 [3.8-8.7] 10.0 [8.5-13.7] 0.02
Range 0.8-83.3 2.5-44.3
HOMA-IR 24 0.9 [0.5-1.1] 1.4 [1.1-1.9] 0.002
Range 0.4-2.0 1.0-5.9
SHBG 33 25.5 [18.2-39.5] 25.0 [14.0-35.5] 0.97
Range 18.0 - 91.0 11.0 - 38.0
Total cholesterol (mmol/L) 33 5.1 [4.4-5.5] 4.9 [4.1-5.7] 0.97
Range 4.1-7.2 3.2-6.2
Low density lipoprotein (LDL) mmol/L 32 3.2 [2.9-3.7] 3.0 [2.0-3.5] 0.70
Range 2.6-5.3 1.4-4.0
High density lipoprotein (HDL) mmol/L 32 1.1 [0.9-1.4] 1.0 [0.9-1.3] 0.70
Range 0.8-1.4 0.8-1.4
Triglycerides (TG) mmol/L 33 1.3 [1.0-2.0] 2.0 [1.2-3.1] 0.21
Range 0.7-2.4 0.8-5.1
Systolic BP (SBP) 30 126.0 [108.0-139.3] 141.0 [125.0-144.5] 0.70
Range 104.0-150.0 107.0-150.0
Diastolic BP (DBP) 30 84.0 [70.0-87.0] 87.0 [74.0-91.5] 0.25
Range 64.0-90.0 68.0-94.0











Absolute IGF-I 10 21.9 ± 4.1 37.1 ± 13.3 0.008
Range 15.9-31.7 23.0-68.1
Age-adjusted IGF-I ratio 10 1.1 ± 0.2 1.7  ± 0.6 0.016
Range 0.7-1.3 0.9-2.8
Dose of GH (mg) 10 0.2 ± 0.0 0.3 ± 0.2 0.049
Range 0.2-0.2 0.1-0.8
BMI (kg/m2) 10 29.4 ± 3.1 30.0 ± 3.6 0.38
Range 24.9-33.7 25.9-35.8
Fasting blood glucose (mmol/L) 10 6.3 ± 3.9 5.5 ± 1.5 0.41
Range 3.2-17.0 4.0 -9.1
HbA1c (mmol/mol 10 37.9 ± 7.4 39.0 ±  8.0 0.36
Range 29.0-53.0 26.0-52.0
Fasting insulin (ug/L) 10 13.1 ± 11.4 12.0 ± 11.8 0.43
Range 2.5-44.3 1.0-43.0
Fasting C-peptide (ug/L) 10 911.0 ±  667.6 915.0 ± 483.7 0.97
Range 814.5-2552.0 256.0-2115.0
HOMA-IR 8 1.9 ± 1.6 1.9 ± 1.8 0.62
Range 1.0-5.9 0.7-6.0
SHBG (mmol/L) 10 27.3 ± 12.5 29.0 ± 11.6 0.31
Range 11.0-48.0 10.0-42.0
Total Cholesterol (mmol/L) 10 4.9 ± 1.0 5.2 ± 0.9 0.08
Range 3.2-6.2 3.4-6.1
Low density lipoprotein (mmol/L) 10 2.8 ± 0.9 3.1 ± 0.9 0.10
Range 1.3-4.0 1.5-4.2
High density lipoprotein (mmol/L) 10 1.1 ± 0.2 1.1 ± 0.2 0.18
Range 0.8-1.4 0.8-1.5
Triglycerides (mmol/L) 10 2.2 ± 1.3 2.3  ± 0.8 0.83
Range 0.8-5.1 1.0-4.2
Systolic BP (mmHg) 10 133.5 ± 14.0 128.2  ± 17.6 0.27
Range 107.0-150.0 107.0-155.0
Diastolic BP (mmHg) 10 81.0 ± 12.1 79.0 ± 11.1 0.43
Range 58.0-94.0 60.0-95.0
Metabolic score (out of 4) 10 3.0 ± 1.4 2.2 ± 0.9 0.07
Range 0.0-4.0 1.0-4.0
AGHDA (out of 25) 10 18.4 ± 5.0 12.0 ± 8.7 0.004
Range 10.0-25.0 1.0-25.0
BDI (out of 63) 10 33.4  ± 16.1 20.7 ± 18.4 0.001
Range 15.0-60.0 3.0-56.0 
Epworth (out of 24) 8 11.0 ± 8.1 10.5 ± 6.8 0.47
Range 0.0-20.0 0.0-18.0
T-score Hip 9 -0.03 ± 1.2
Range -1.2 - +2.5
T-score Spine 9 0.08 ± 1.2















































































































Group: F(1, 31)=0.05, P=0.37




Group: F(1, 31)=0.14, P=0.71






































a	=	correction	for	all	covariates	(time	since	injury,	time	between	scans,	gender,	age	at	first	scan,	TBI	severity)	 	 	 	 	
Data	displayed	as	median	[IQR]	range.	 Group,	time	and	group*time	analysis	performed	using	a	repeated	measures	ANOVA.	 	 	 	
Note:		Matrix	reasoning,	People	test,	Logical	memory:	higher	score	equals	better	performance;	Trail-making,	Stroop,	letter	fluency:	lower	score	equals	better	
cognition	 	 	 	 	
Abbreviations:	DKEFS,	Delis-Kaplan	executive	function	system;	(s),	seconds;	SF-36;	WASI,	Wechsler	Adult	Intelligence	Scale;	WTAR,	Wechsler	Test	of	Adult	
Reading.	 	 	 	 	
	
Cognitive domain Cognitive variable n (no GHR)
n (with 







Pre-morbid intelligence: reading ability WTAR raw score 20 10 41.0 [36.0-46.0] 43.0 [34.5-47.8] 0.091 0.939 0.943
Intellectual ability WASI matrix reasoning (non-verbal) 20 10 29.0 [24.0-30.0] 29.0 [26.3-31.0] 0.054 0.317 0.741
Memory: associative memory People test (total score) 20 10 24.0 [20.0-28.0] 27.5 [20.3-31.0] 0.067 0.922 0.218
Memory: immediate recall Logical memory I Total 20 10 41.0 [36.0-49.5] 45.0 [34.5-51.0] 0.552 0.107 0.108
Logical memory II Total 20 10 26.0 [20.5-34.0] 26.5 [22.3-36.0] 0.666 0.635 0.629
Memory: delayed recall Logical memory retention 20 10 86.7 [78.4-96.1] 90.8 [83.4-100.0] 0.667 0.632 0.630
Processing speed: visual search/complex Trail Making Test Trail A (s) 20 10 24.0 [18.0-31.0] 20.5 [16.3-23.8] 0.188 0.224 0.261
Trail Making Test Trail B (s) 20 10 47.0 [35.0-67.0] 44.0 [31.0-60.0] 0.275 0.170 0.803
Processing speed: naming/reading Stroop Colour Naming (s) 20 10 31.0 [27.5-40.5] 30.5 [26.5-35.0] 0.068 0.382 0.135
Stroop Word Reading (s) 20 10 22.0 [18.5-26.0] 22.0 [19.0-24.8] 0.837 0.326 0.254
Executive function: alternating-switch cost Trail Making Test Trail B minus A (s) 20 10 23.0 [15.5-37.0] 19.0 [14.3-35.5] 0.846 0.296 0.466
Cognitive flexibility Colour Word Stroop Inhibition/switching (s) 20 10 61.0 [51.0-74.0] 52.0 [46.0-57.0] 0.006 0.712 0.871






































































































































































































































































































































































































A  Image processing B  Blood data processing 



















































































Subject	 Genotype	 Age	(yrs.)	 Gender	 Weight	(kg)	
1	 HAB	 47.9	 M	 97.9	
2	 HAB	 35.5	 M	 72.1	
3	 HAB	 34.4	 M	 94.6	
4	 HAB	 48.1	 F	 69.7	
5	 HAB	 28.4	 M	 96.6	
6	 MAB	 49.2	 M	 87.5	
7	 MAB	 39.8	 F	 70.3	
8	 MAB	 31.0	 F	 74.2	
9	 MAB	 56.2	 M	 65.4	



























































































































(A)	Model	 fits	 are	 shown	 for	 one-tissue	 compartmental-model	 (reversible	 1TC)	 black	 dashed	 line	
and	two-tissue	compartmental-model	(reversible	2TC),	red	solid	line)	against	a	time	activity	curve	























































































































































































































































































































































































































































































































































































Age 39.8	[34.4-48.1] 46.0	[38.9-56.4] 0.41
Range 28.4-56.2 35.0-65.7
Males	(n	%) 8	(72.7%) 10	(83.3%) 0.91
HABs	(n	%) 5	(45.5%) 8	(66.7%) 0.55
Weight	(kg) 87.5	[70.3-94.6] 79.0	[69.3-86.5] 0.68
Range 65.4-97.9 66.8-100.6












Age 41.4	[37.9-52.6] 52.6	[45.0-63.6] 0.15
Range 35.0-59.7 44.0-65.7
Males	(n	%) 7	(87.5%) 3	(75%) 0.78
Moderate-to-severe	severity	(n	%) 7	(87.5%) 4	(100%) 0.71
Any	structural	lesion	(n%) 6	(75%) 3	(75%) 0.48
Time	since	injury 7.1	[4.5-11.2] 15.6	[9.6-25.6] 0.15
Range 2.9-152.0 8.9-67.7
MetS	(n	%) 2	(25%) 3	(75%) 0.30
Weight 75.3	[69.3-80.5] 90.3	[72.1-98.5] 0.15
Range 66.8-81.0 66.8-100.6

























1 male 38.6 White	caucasian Doctorate moderate-severe 9.2 0.51 HAB Yes
2 male 43.0 White	caucasian A	Level probable 152.0 0.49 HAB No
3 male 37.7 South	asian NVQ moderate-severe 11.9 0.50 HAB Yes
4 male 35.0 White	caucasian Masters moderate-severe 7.4 0.52 HAB No
5 male 59.7 White	caucasian MBA moderate-severe 4.4 0.50 HAB No
6 female 57.2 White	caucasian None moderate-severe 27.6 0.51 MAB Yes
7 female 54.0 White	caucasian O	level moderate-severe 4.8 0.54 HAB No
8 female 48.2 White	caucasian BA moderate-severe 2.9 0.50 HAB No
9 male 44.0 White	caucasian Degree moderate-severe 19.5 0.51 MAB Yes
10 male 48.0 White	caucasian Degree moderate-severe 11.7 0.50 MAB No
11 male 39.8 Chinese None moderate-severe 6.8 n/a HAB No






no. Mode	of	injury PTA GCS LOC Other	Injuries	at	TBI Acute	clinical	imaging	findings Baseline	MRI	Report	






2 RTA:	motorcylist <24	hrs NK nil R	tibia	fracture ?Bifrontal	hyperintensity Normal





























8 Fall 24-48	hrs NK <1	hr superficial	injuries
R	temporal	lobe	fracture,	
orbitofrontal	contusion Gliosis	R	orbit	and	R	temporal	lobe
























































4 Attention,	fatigue,	memory,	labile	mood,	BPPV Renal	colic nil yes
5
Slowed	thinking,	memory,	lack	of	insight,	









7 BPPV nil nil no
8
Slowed	thinking,	impaired	attention,	memory	

























































1 131 75 94 28.7 168 81.0 24.7 11.8 857 26 38 5.6 1.56 6.5 1.21 4.68 1.34 no no no yes
2 114 67 93 25.8 174 78.2 20.2 7.9 690 13 37 5.2 1.04 5.2 0.94 3.25 2.22 no no no no
3 116 67 95 23.7 185 80.8 23.3 20.4 1731 23 36 5.0 2.59 6.0 0.81 4.17 2.25 no no no yes
4 114 65 76 23.0 177 72.1 14.6 6.0 436 38 34 4.7 0.77 7.4 1.33 5.62 1.00 no no no no
5 109 66 86 25.1 163 66.8 22.4 3.2 269 ND 38 5.1 0.42 7.1 1.34 5.20 1.23 no no no no
6 139 70 100 28.9 152 66.8 42.0 3.2 740 104 44 6.3 0.44 4.7 1.62 2.50 1.27 yes yes no yes
7 122 76 85 24.8 171 72.4 23.0 5.1 502 62 36 4.7 0.65 5.6 1.43 3.67 1.11 no no no no
8 116 64 85 29.6 164 79.7 35.4 6.0 553 155 33 4.7 0.77 5.4 1.47 3.54 0.86 no no no no
9 133 77 112 33.1 167 92.3 33.9 29.8 1464 13 53 8.0 4.13 5.4 0.83 3.41 2.55 no no yes yes
10 133 91 110 32.1 177 100.6 29.2 13.2 1089 27 33 5.4 1.73 5.4 1.05 3.89 1.02 no no no no
11 138 90 90 27.7 157 68.3 21.3 4.0 264 31 42 5.0 0.52 7.9 1.38 5.87 1.42 no no no no





























































































Parent fraction whole group









































































































Patient 2: Parent fraction







Patient 3: Parent fraction







Patient 5: Parent fraction












Patient 2: Plasma radioactivity












Patient 3: Plasma radioactivity












Patient 2: WB radioactivity











Patient 5: WB radioactivity































Patient 5: Plasma radioactivity




































Patient 9: Parent fraction









Patient 10: Parent fraction














Patient 10: Plasma radioactivity












Patient 9: WB radioactivity







Patient 9: Parent fraction
Scan 1
Scan 2












Patient 9: Plasma radioactivity


































Patient 10: WB radioactivity








Patient 6: Parent fraction












Patient 6: Plasma radioactivity

























































































































n 7 7 7 7
Frontal	Lobe 0.0087 0.55 0.1102 0.02 0.0276 0.02 0.0094 0.02
[0.0079-0.0113] [0.0948-0.1596] [0.0244-0.0329] [0.0053-0.0144]
Parietal	Lobe 0.0104 0.06 0.1335 0.24 0.0293 0.24 0.0066 0.24
[0.0096-0.0133] [0.1191-0.1770] [0.0245-0.0323] [0.0051-0.0127]
Temporal	Lobe 0.0129 0.06 0.1822 1.00 0.0478 1.00 0.0168 0.55
[0.0098-0.0194] [0.1476-0.2301] [0.0301-0.0646] [0.0121-0.0175]
Occipital	Lobe 0.0141 0.55 0.2528 0.24 0.0472 1.00 0.0162 0.55
[0.0161-0.4665] [0.2003-31.7664] [0.0362-0.0979] [0.0096-0.0186]
Thalamus 0.0142 1.00 0.1353 0.24 0.0417 0.24 0.0149 1.00
[0.0094-0.0745] [0.1210-21.6753] [0.0307-0.1652] [0.0101-0.0182]
Striatum 0.0081 0.06 1.7700 1.00 2.8427 0.24 0.0854 0.24
0.0044-0.0422 [0.6328-7.1387] [0.3940-4.8181] [0.0234-0.1304]
Cerebellum 0.0179 0.06 0.2220 1.00 0.0302 1.00 0.0142 0.55
[0.0142-0.5333] [0.1647-31.7753] [0.0267-0.0848] [0.0078-0.0172]
Hypothalamus	grey 0.0037 0.55 0.7070 0.24 6.0323 1.00 0.1620 1.00
[0.0033-0.0082] [0.6508-1.6766] [4.6810-7.0465] [0.1387-0.1689]
MABs K1 K2 K3 K4
n 4 4 4 4
Frontal	Lobe 0.0028 7.1624 5.9343 0.1436
[0.0010-0.0792] [1.0090-14.0856] [2.8968-6.6064] [0.0663-0.7196]
Parietal	Lobe 0.0030 0.5739 6.4566 0.0853
[0.0013-0.0058] [0.1708-1.4901] [2.6549-12599.4987] [0.0214-0.1374]
Temporal	Lobe 0.0048 0.7848 3.5199 0.0080
[0.0016-0.0076] [0.1473-7.3992] [0.0304-15304.2525] [0.0036-0.0770]
Occipital	Lobe 0.0237 5.4155 0.0627 0.0121
[0.0061-0.6691] [0.2756-36.2639] [0.0393-533.3176] [0.0010-0.1682]
Thalamus 0.0845 12.9516 3.4038 0.0206
[0.0019-0.4232] [3.7036-49.3591] [0.2325-12728.5189] [0.0093-0.0599]
Striatum 0.0013 1.7550 7.3367 0.2158
[0.0006-0.0026] [1.030-2.2570] [2.7557-25.5438] [0.1613-0.7595]
Cerebellum 0.0080 0.2414 0.0288 0.0056
[0.0039-0.0090] [0.1707-7.1481] [0.0239-4349.6958] [0.0020-0.6344]
Hypothalamus	grey 0.0017 6.1179 6.9653 0.1756

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3	 M	 GH	as	a	child	for	~5	years	for	short	stature	 No	 Yes	 No	





6	 M	 GH	for	short	stature	from	~9	years	for	~5	years	 Yes	 No	 Yes	
7	 M	
GH	as	an	adolescent	for	~3	years	for	
panhypopituitarism	
No	 No	 No	
8	 M	
GH	for	restricted	growth	
from	16	years	for	~2	years	
Yes	 No	 Yes	
	
Summary	table	of	the	clinical	indications	for	c-hGH	treatment	in	childhood	and	incidence	of	
β-amyloid	for	each	patient	(adapted	from	article	text	and	supplementary	information)	
	
